Acalabrutinib information

Acalabrutinib
Clinical data
Trade names	Calquence
Other names	ACP-196
AHFS/Drugs.com	Monograph
MedlinePlus	a618004
License data	US DailyMed: Acalabrutinib;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
ATC code	L01EL02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide;
CAS Number	1420477-60-6;
PubChem CID	71226662;
DrugBank	DB11703;
ChemSpider	36764951;
UNII	I42748ELQW;
KEGG	D10893;
ChEBI	CHEBI:167707;
ChEMBL	ChEMBL3707348;
PDB ligand	XQQ (PDBe, RCSB PDB);
ECHA InfoCard	100.247.121
Chemical and physical data
Formula	C26H23N7O2
Molar mass	465.517 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5;
	InChI InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1; Key:WDENQIQQYWYTPO-IBGZPJMESA-N;

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL).^[7] It may be used both in relapsed as well as in treatment-naive settings.^[8]

Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells.^[7] It is a second generation Bruton's tyrosine kinase inhibitor.^[9]^[10] Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow.^[5] By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in CLL, thereby delaying progression of the cancer.^[5]

Acalabrutinib was approved for medical use in the United States in 2017,^[7] and in the European Union in November 2020.^[5]

^ "Acalabrutinib (Calquence) Use During Pregnancy". Drugs.com. 23 October 2019. Retrieved 28 March 2020.
^ https://www.tga.gov.au/resources/auspmd/calquence
^ "Summary Basis of Decision (SBD) for Calquence". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Calquence- acalabrutinib capsule, gelatin coated". DailyMed. 22 November 2019. Retrieved 11 November 2020.
^ ^a ^b ^c ^d "Calquence EPAR". European Medicines Agency. 20 July 2020. Retrieved 11 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Calquence Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ ^a ^b ^c "Acalabrutinib Monograph for Professionals". Drugs.com. Retrieved 16 March 2019.
^ "FDA approves new treatment for adults with mantle cell lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 31 October 2017. Retrieved 28 March 2020.
^ Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. (January 2016). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia". The New England Journal of Medicine. 374 (4): 323–332. doi:10.1056/NEJMoa1509981. PMC 4862586. PMID 26641137.
^ Wu J, Zhang M, Liu D (March 2016). "Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor". Journal of Hematology & Oncology. 9: 21. doi:10.1186/s13045-016-0250-9. PMC 4784459. PMID 26957112.

[Drugs.com_pregnancy-1] "Acalabrutinib (Calquence) Use During Pregnancy". Drugs.com. 23 October 2019. Retrieved 28 March 2020.

[2] ttps://www.tga.gov.au/resources/auspmd/calquence

[3] "Summary Basis of Decision (SBD) for Calquence". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[Calquence_FDA_label-4] "Calquence- acalabrutinib capsule, gelatin coated". DailyMed. 22 November 2019. Retrieved 11 November 2020.

[Calquence_EPAR-5] "Calquence EPAR". European Medicines Agency. 20 July 2020. Retrieved 11 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[6] "Calquence Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[AHFS2019-7] "Acalabrutinib Monograph for Professionals". Drugs.com. Retrieved 16 March 2019.

[8] "FDA approves new treatment for adults with mantle cell lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 31 October 2017. Retrieved 28 March 2020.

[Byrd_2015-9] Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. (January 2016). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia". The New England Journal of Medicine. 374 (4): 323–332. doi:10.1056/NEJMoa1509981. PMC 4862586. PMID 26641137.

[Wu_2016-10] Wu J, Zhang M, Liu D (March 2016). "Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor". Journal of Hematology & Oncology. 9: 21. doi:10.1186/s13045-016-0250-9. PMC 4784459. PMID 26957112.

Acalabrutinib information

and 26 Related for: Acalabrutinib information

Acalabrutinib

Quetiapine

Propofol

Pascal Soriot

Rosuvastatin

Chronic lymphocytic leukemia

Astra AB

Mantle cell lymphoma

Eculizumab

AstraZeneca

Omeprazole

Tamoxifen

Zeneca

Metoprolol

Durvalumab

Ticagrelor

Anastrozole

Dapagliflozin

Brompheniramine

Ravulizumab

Esomeprazole

Andexanet alfa

Atenolol

Trastuzumab deruxtecan

Bicalutamide

MedImmune